CSRT.L Regulatory News (CSRT)

News Release

22 October 2014

Consort Medical plc

Development Contract Award

Consort Medical plc ("Consort Medical", "Group") (LSE: CSRT), is pleased to announce the award of a new development contract.

Bespak has been awarded a development contract for a new drug / device product which incorporates its ASI® autoinjector. The contract is with a global generic company, with contract details confidential at present. Going forwards the project will be referred to as INJ650 on the Group's product development pipeline.

Jonathan Glenn, Consort Medical's Chief Executive, commented:

"The award of this ASI autoinjector development contract confirms Bespak's growing presence in the significant Injectables market, following the launch of the Dr. Reddy's Sumatriptan autoinjector in February 2014."

-Ends-

Enquiries:

Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

The Group has facilities in King's Lynn, Cambridge, Nelson and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.